22nd Century Group, Inc.
22nd Century Group, Inc. (XXII) Stock Overview
Explore 22nd Century Group, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
87.2M
P/E Ratio
-0.82
EPS (TTM)
$1212.10
ROE
-5.42%
XXII Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of 22nd Century Group, Inc. (XXII) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $549.40.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.82 and a market capitalization of 87.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
Lawrence D. Firestone
56
500 Seneca Street, Mocksville, NY
2011